REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Stock Information for 2seventy bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 2seventy bio Inc.

REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.